Recent Peer-Reviewed Publication Confirms Patient Satisfaction with Multiple Allergy Immunotherapy Options
17 nov. 2021 09h30 HE
|
Allovate, LLC
New York, Nov. 17, 2021 (GLOBE NEWSWIRE) -- A recent article in the peer-reviewed journal International Forum of Allergy and Rhinology reported the results of a survey offered to individuals with...
Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit
22 juil. 2021 16h57 HE
|
Intrommune Therapeutics
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics to Present at BIO Digital 2021
17 juin 2021 09h11 HE
|
Intrommune Therapeutics
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Names Chief Operating Officer
25 mars 2021 09h10 HE
|
Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
12 mars 2021 09h30 HE
|
Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...
Intrommune Therapeutics Publishes Peanut Allergy and Immunotherapy Report
23 févr. 2021 12h00 HE
|
Intrommune Therapeutics
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly immunotherapy platform for the treatment of...
Allovate Therapeutics Extends Free Allerdent® Program
23 juil. 2020 15h37 HE
|
Allovate, LLC
New York, July 23, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it has extended its free Allerdent® program. Allerdent® is a...
Allovate Therapeutics Provides Free Allerdent® To Physicians
06 mai 2020 09h05 HE
|
Allovate, LLC
New York, May 06, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available...
Allovate Therapeutics Appoints Bob Pomrenke as CEO
02 avr. 2019 14h04 HE
|
Allovate, LLC
New York, April 02, 2019 (GLOBE NEWSWIRE) -- Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the...